Hepatocellular Carcinoma (HCC), Where do we stand? Current situation.
BCLC
Hepatocellular Carcinoma
MELD
Staging of HCC
Journal
Pakistan journal of medical sciences
ISSN: 1682-024X
Titre abrégé: Pak J Med Sci
Pays: Pakistan
ID NLM: 100913117
Informations de publication
Date de publication:
Historique:
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
4
2020
Statut:
ppublish
Résumé
To identify the stage of Hepatocellular Carcinoma (HCC) at the time of presentation. This cross sectional observational prospective study was carried out at Gastro Department of Combined Military Hospital (CMH) Multan from August 2017 to December 2018. Patients were diagnosed on the basis of alpha fetoprotein, abdominal ultrasound, triphasic contrast enhanced computerized tomography (CECT). They were evaluated for etiology including Hepatitis B, C and non B & C. The patients were inquired about the previous treatment and when they came to know about the HCC. Staging of the tumor was done on the basis BCLC (Barcelona cancer liver clinic) and Melan's criteria. Performance status (PS) of the patient was checked by Eastern Cooperative Oncology Group (ECOG) criteria. Severity of cirrhosis was assessed by CTP (Child Turcotte Pugh) and Model for end stage liver disease (MELD) score. The data was analyzed in IBM SPSS version 22. Out of 135 patients 78% were males and 22% females. Age Mean SD was 58.81± 9.366. Frequency of hepatitis C, B, combined B, C and non-B non-C was 80%, 11%, 2.8% and 6.2% respectively. 96(73.8%) never got the treatment before for Hepatitis. 81(62.3%) came to know first time on this index admission. Maximum numbers of patients were in BCLC stage B i.e. 82(55.2%) with ECOG grade of one i.e.57 (39.3%), at the time of presentation. Mean MELD and CTP score were 12.24, 7.34 (class B) respectively. HCV was the most common in HCC, never treated before, presented for the first time in advance stage of the disease where very limited treatment options left behind.
Identifiants
pubmed: 32292431
doi: 10.12669/pjms.36.3.1594
pii: PJMS-39-344
pmc: PMC7150378
doi:
Types de publication
Journal Article
Langues
eng
Pagination
344-348Informations de copyright
Copyright: © Pakistan Journal of Medical Sciences.
Déclaration de conflit d'intérêts
Conflict of interest and funding involved: There is no conflict of interest or funding involved.
Références
Gastroenterol Hepatol (N Y). 2015 Jan;11(1):38-46
pubmed: 27099571
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Hepat Mon. 2012 Oct;12(10 HCC):e6023
pubmed: 23166534
BMC Res Notes. 2013 Apr 08;6:137
pubmed: 23566475
Clinics (Sao Paulo). 2010;65(12):1285-90
pubmed: 21340216
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Clin Oncol. 2010 Sep 1;28(25):3994-4005
pubmed: 20679622
J Natl Cancer Inst. 2008 May 21;100(10):698-711
pubmed: 18477802
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S27-33
pubmed: 25755607
Gastroenterology. 2008 May;134(5):1342-51
pubmed: 18471511
Gut Liver. 2016 May 23;10(3):332-9
pubmed: 27114433
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Hepatology. 2007 Mar;45(3):797-805
pubmed: 17326206
Therap Adv Gastroenterol. 2011 Jan;4(1):5-10
pubmed: 21317990
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):793-9
pubmed: 22374994
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Gastroenterology. 2017 Mar;152(4):812-820.e5
pubmed: 27889576
Semin Oncol. 2012 Aug;39(4):384-98
pubmed: 22846857
J Coll Physicians Surg Pak. 2015 Apr;25(4):259-63
pubmed: 25899190
Liver Int. 2015 Sep;35(9):2155-66
pubmed: 25752327
Asian Pac J Cancer Prev. 2014;15(18):7563-7
pubmed: 25292029
Eur J Cancer. 2012 Mar;48(5):599-641
pubmed: 22424278
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124